Evolution of Untreated Hereditary Hemochromatosis in the Busselton Population: A 17-Year Study

Mayo Clinic Proceedings

Volumn 79, Issue 3, 2004, Pages 309-313

  Olynyk, John K ^a,b,c,e   Hagan, Simone E ^b   Cullen, Digby J ^b,c   Beilby, John ^c,d   Whittall, Davina E ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c Busselton Pop Med Res Foundation   (Australia)

^d PATHWEST LABORATORY MEDICINE   (Australia)

^e Western Australian Institute of Medical Research   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; TRANSFERRIN;

ADULT; ARTICLE; AUSTRALIA; C282Y GENE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; FEMALE; FERRITIN BLOOD LEVEL; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC DISORDER; HEALTH SURVEY; HEMOCHROMATOSIS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MALE; PATHOGENESIS; SCORING SYSTEM;

EID: 1442282237     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.3.309     Document Type: Article

References (26)

1. Trinder D, Fox C, Vautier G, Olynyk JK. Molecular pathogenesis of iron overload. Gut. 2002;51:290-295.
2. Feder NJ, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408.
3. Burt MJ, George PM, Upton JD, et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut. 1998;43:830-836.
4. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341:718-724.
5. Beutler E, Gelbart T, West C, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis. 1996;22:187-194.
6. Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H [letter]. Nat Genet. 1996;14:249-251.
7. Jouanolle AM, Gandon G, Jezequel P, et al. Haemochromatosis and HLA-H [letter]. Nat Genet. 1996;14:251-252.
8. Adams PC, Campion ML, Gandon G, LeGall JY, David V, Jouanolle AM. Clinical and family studies in genetic hemochromatosis: microsatellite and HFE studies in five atypical families. Hepatology. 1997;26:986-990.
9. UK Haemochromatosis Consortium. A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut. 1997;41: 841-844.
10. Moirand R, Jouanolle AM, Brissot P, LeGall JY, David V, Deugnier Y. Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology. 1999;116:372-377.
11. Gochee P, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation [published correction appears in Gastroenterology. 2002;122:1191]. Gastroenterology. 2002;122:646-651.
12. Gochee P, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation [published correction appears in Gastroenterology. 2002;122:1191]. Gastroenterology. 2002;122:646-651.
13. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology. 1999;116:193-207.
14. Waalen J, Felitti V, Gelbart T, Ho NJ, Beutler E. Penetrance of hemochromatosis. Blood Cells Mol Dis. 2002;29:418-432.
15. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol. 2001;36:1108-1115.
16. McCune CA, Al-Jader LN, May A, Hayes SL, Jackson HA, Worwood M. Hereditary haemochromatosis: only 1% of adult HFEC282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet. 2002;111:538-543.
17. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359:211-218.
18. Welborn TA, Curnow DH, Wearne JT, Cullen KJ, McCall MG, Stenhouse NS. Diabetes detected by blood-sugar measurement after a glucose load: report from the Busselton survey, 1966. Med J Aust. 1968;2:778-783.
19. Knuiman MW, Vu HT. Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. J Epidemiol Community Health. 1997; 51:515-519.
20. Knuiman MW, Divitini ML, Olynyk JK, Cullen DJ, Bartholomew HC. Serum ferritin and cardiovascular disease: a 17-year follow-up study in Busselton, Western Australia. Am J Epidemiol. 2003;158:144-149.
21. Hovell CJ, Collett JA, Vautier G, et al. High prevalence of coeliac disease in a population-based study from Western Australia: a case for screening? Med J Aust. 2001;175:247-250.
22. Deugnier Y, Jouanolle AM, Chaperon J, et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked hemochromatosis: a study of 9396 French people. Br J Haematol. 2002;118:1170-1178.
23. Yamashita C, Adams PC. Natural history of the C282Y homozygote for the hemochromatosis gene (HFE) with a normal serum ferritin level. Clin Gastroenterol Hepatol. 2003;1:388-391.
24. Skikne B, Baynes RD. Iron absorption. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron Metabolism in Health and Disease. London, England: WB Saunders Co; 1994:151-187.
25. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med. 1999;130:953-962.
26. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology. 1998;115:929-936.